The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress

  • Authors:
    • Ali Parlar
    • Seyfullah Oktay Arslan
    • Muhammed Fatih Doğan
    • Saliha Ayşenur Çam
    • Alper Yalçin
    • Ebru Elibol
    • Mehmet Kaya Özer
    • Fatih Üçkardeş
    • Halil Kara
  • View Affiliations

  • Published online on: September 18, 2018     https://doi.org/10.3892/etm.2018.6753
  • Pages: 4900-4908
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the role of cannabinoid 2 (CB2) receptors in a rat model of acute inflammation. Therefore, the potential of anti‑inflammatory effects of CB2 receptor agonist (GW405833), CB2 receptor antagonist (AM630), and diclofenac, were investigated in carrageenan induced paw oedema in rats: as were assessed by measuring paw oedema; myeloperoxidase (MPO) activity in paw tissue; malondialdehyde (MDA) concentration; glutathione (GSH) level in paw tissue for oxidant/antioxidant balance; cytokine (interleukin‑1β, IL‑1β; tumour necrosis factor‑α, TNF‑α) levels in serum; histopathology of paw tissue for inflammatory cell accumulations. The results showed that GW405833 or diclofenac significantly reduced carrageenan‑induced paw oedema. GW405833 also inhibited the increase of MPO activity, the recruitment of total leukocytes and neutrophils, and MDA concentration during carrageenan‑induced acute inflammation, along with reversed nearly to the normal levels the increased of TNF‑α, and IL‑1β in serum. AM630 did not affect inflammation alone however clearly reversed the effects of agonist when co‑administered. The mechanism of GW405833's suppression of inflammation is supported by these results, which are achieved by the inhibition of neutrophil migration, which regulates the reduction of oxidative stress, TNF‑α and IL‑1β levels. Finally, the activation of CB2 receptor, by selective agonist, has a major role in peripheral inflammation, and in the near future, targeting the peripheral cannabinoid system as a promising alternative to treat inflammation diseases may be considered a novel pharmacologic approach.
View Figures
View References

Related Articles

Journal Cover

December-2018
Volume 16 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Parlar A, Arslan SO, Doğan MF, Çam SA, Yalçin A, Elibol E, Özer MK, Üçkardeş F and Kara H: The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress. Exp Ther Med 16: 4900-4908, 2018
APA
Parlar, A., Arslan, S.O., Doğan, M.F., Çam, S.A., Yalçin, A., Elibol, E. ... Kara, H. (2018). The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress. Experimental and Therapeutic Medicine, 16, 4900-4908. https://doi.org/10.3892/etm.2018.6753
MLA
Parlar, A., Arslan, S. O., Doğan, M. F., Çam, S. A., Yalçin, A., Elibol, E., Özer, M. K., Üçkardeş, F., Kara, H."The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress". Experimental and Therapeutic Medicine 16.6 (2018): 4900-4908.
Chicago
Parlar, A., Arslan, S. O., Doğan, M. F., Çam, S. A., Yalçin, A., Elibol, E., Özer, M. K., Üçkardeş, F., Kara, H."The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress". Experimental and Therapeutic Medicine 16, no. 6 (2018): 4900-4908. https://doi.org/10.3892/etm.2018.6753